[Skip to Navigation]
Sign In

Year

Day

October 21, 2021
Original Investigation

Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma

Abstract Full Text
JAMA Oncol. Published online October 21, 2021. doi:10.1001/jamaoncol.2021.4544

This cohort study assesses the clinical activity and toxic effects of cabozantinib to treat brain metastases in patients with metastatic renal cell carcinoma.

Update of Incidence, Prevalence, Survival, and Initial Treatment in Patients With Non–Small Cell Lung Cancer in the US

Abstract Full Text
JAMA Oncol. Published online October 21, 2021. doi:10.1001/jamaoncol.2021.4932

This cross-sectional epidemiological analysis calculated the most recent epidemiological estimates of incidence, prevalence, and survival in patients with non–small cell lung cancer, and describes initial treatment overall and by stage in the US.

Cost-effectiveness Evaluation of the 2021 US Preventive Services Task Force Recommendation for Lung Cancer Screening

Abstract Full Text
JAMA Oncol. Published online October 21, 2021. doi:10.1001/jamaoncol.2021.4942

This economic evaluation assessed the cost-effectiveness of the 2021 US Preventive Services Task Force recommendation for lung cancer screening compared with the 2013 recommendation and alternative screening strategies.

Research Letter

Association of Smoking Initiation and Cessation Across the Life Course and Cancer Mortality: Prospective Study of 410 000 US Adults

Abstract Full Text
JAMA Oncol. Published online October 21, 2021. doi:10.1001/jamaoncol.2021.4949

This cohort study investigates the association between age at smoking initiation and cessation and cancer mortality using National Health Interview Survey data.

Viewpoint

A Coordinated Policy Approach to Address Medical Financial Toxicity

Abstract Full Text
JAMA Oncol. Published online October 21, 2021. doi:10.1001/jamaoncol.2021.3606
Editorial

The Long, Slow Road to Lung Cancer Cure

Abstract Full Text
JAMA Oncol. Published online October 21, 2021. doi:10.1001/jamaoncol.2021.4711
October 14, 2021
Original Investigation

Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib

Abstract Full Text
JAMA Oncol. Published online October 14, 2021. doi:10.1001/jamaoncol.2021.4664

This genetic association study examines whether patients who harbor specific clonal hematopoiesis of indeterminate potential variants before rucaparib treatment may be at an increased risk of developing therapy-related myeloid neoplasms.

Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial

Abstract Full Text
open access
JAMA Oncol. Published online October 14, 2021. doi:10.1001/jamaoncol.2021.4761

This nonrandomized clinical trial evaluates the treatment outcomes and safety of mobocertinib treatment in patients with previously treated EGFR exon 20 insertion–positive metastatic non–small cell lung cancer.

Research Letter

Occurrence of Pancytopenia Among Patients With Cancer Treated With Poly(Adenosine Diphosphate–Ribose) Polymerase Inhibitors: A Pharmacoepidemiologic Study

Abstract Full Text
JAMA Oncol. Published online October 14, 2021. doi:10.1001/jamaoncol.2021.4672

This cross-sectional study uses pharmacovigilance data to investigate the occurrence of pancytopenia among patients with cancer treated with poly(adenosine diphosphate–ribose) polymerase inhibitors and examines the clinical features of pancytopenia related to these drugs.

Review

Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates: A Review

Abstract Full Text
JAMA Oncol. Published online October 14, 2021. doi:10.1001/jamaoncol.2021.3595

This narrative review describes the diagnosis and treatment of interstitial lung disease associated with the use of antibody-drug conjugates in patients with various types of cancer, including breast, colorectal, gastric, and lung cancer among others.

Editorial

Poly(ADP-Ribose) Polymerase Inhibitors and Myeloid Neoplasm Risk—Clues to a Mechanistic Connection?

Abstract Full Text
JAMA Oncol. Published online October 14, 2021. doi:10.1001/jamaoncol.2021.4639
Poetry and Oncology

Say Hi

Abstract Full Text
free access
JAMA Oncol. Published online October 14, 2021. doi:10.1001/jamaoncol.2021.4315
October 7, 2021
Original Investigation

Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor–Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. Published online October 7, 2021. doi:10.1001/jamaoncol.2021.4301

This randomized clinical trial investigates fulvestrant-palbociclib vs letrozole-palbociclib as initial therapy for endocrine-sensitive, hormone receptor–positive, ERBB2-negative breast cancer.

Performance of the McGill Interactive Pediatric OncoGenetic Guidelines for Identifying Cancer Predisposition Syndromes

Abstract Full Text
JAMA Oncol. Published online October 7, 2021. doi:10.1001/jamaoncol.2021.4536

This diagnostic study of children with cancer evaluates the clinical utility of the McGill Interactive Pediatric OncoGenetic Guidelines in cancer predisposition syndrome prediction.

Brief Report

Nodal Recurrence in Patients With Node-Positive Breast Cancer Treated With Sentinel Node Biopsy Alone After Neoadjuvant Chemotherapy—A Rare Event

Abstract Full Text
JAMA Oncol. Published online October 7, 2021. doi:10.1001/jamaoncol.2021.4394

This cohort study examines nodal recurrence rates in patients with clinically node-positive cancer treated with sentinel lymph node biopsy alone after neoadjuvant chemotherapy.

Viewpoint

Adjuvant Chemotherapy for Stage I Pancreatic Ductal Adenocarcinoma—Is It Based on Evidence or Clinical Wisdom?

Abstract Full Text
JAMA Oncol. Published online October 7, 2021. doi:10.1001/jamaoncol.2021.3603

This Viewpoint examines the role of adjuvant chemotherapy, radiotherapy, or combined treatment for stage 1 pancreatic ductal adenocarcinoma.

×